TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02523105

Intervention type: DEVICE
Group type: OTHER
Intervention: EEG monitoring
Description: EEG evaluation will be done using two off the shelf EEG devices for research and consumer use. The first one is a device called MindWave by NeuroSky ltd (http://neurosky.com) the second called EPOC by Emotiv ltd (https://emotiv.com/epoc.php).~EEG evaluation will be conducted for a total duration of 20 minutes with and without auditory stimulation. The auditory stimulation will be performed using standard headphone or earphones to reduce external noises.

Intervention type: DEVICE
Group type: OTHER
Intervention: EEG monitoring
Description: EEG evaluation will be done using two off the shelf EEG devices for research and consumer use. The first one is a device called MindWave by NeuroSky ltd (http://neurosky.com) the second called EPOC by Emotiv ltd (https://emotiv.com/epoc.php).~EEG evaluation will be conducted for a total duration of 20 minutes with and without auditory stimulation. The auditory stimulation will be performed using standard headphone or earphones to reduce external noises.
Study: NCT03384719

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 35 g protein (30% milk + 70% rapeseed)
Description: The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.~Protein powder ingredients (all are food quality):~* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)~* Rapeseed protein isolate: Isolexx® (BioExx, Saskatoon, Canada)~* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 35 g protein (54% milk + 46% rapeseed)
Description: The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.~Protein powder ingredients (all are food quality):~* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)~* Rapeseed protein isolate: Isolexx® (BioExx, Saskatoon, Canada)~* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 35 g protein (100% milk)
Description: The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.~Protein powder ingredients (all are food quality):~* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)~* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day.
Study: NCT02000856

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot juice

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice
Study: NCT03270007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: different from primary chemotherapy(containing anthracycline or paclitaxel)
Study: NCT01752257

Intervention type: DRUG
Group type: OTHER
Intervention: EF5 Hypoxia
Description: EF5 is a dye used to measure hypoxia
Study: NCT02636400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: controlled ovarian stimulation with gonadotropins + intrauterine insemination
Study: NCT01093209

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Interferential Laser Therapy
Description: PROCEDURE: Interventional group: Two independents and identical probes. Energy dose per point and per probe: 5 J. Continuous emission. Treatment time:8 minutes. Sessions: 10. Frequency of the sessions: daily. Irradiation technique: handily, in contact and at 7 points over distal pathway of median nerve.Control group: Sham laser:650 nm.Scanning mode.Outpout power:1 mW.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interferential Laser Therapy
Description: PROCEDURE: Interventional group: Two independents and identical probes. Energy dose per point and per probe: 5 J. Continuous emission. Treatment time:8 minutes. Sessions: 10. Frequency of the sessions: daily. Irradiation technique: handily, in contact and at 7 points over distal pathway of median nerve.Control group: Sham laser:650 nm.Scanning mode.Outpout power:1 mW.
Study: NCT02368405

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants in the control group will receive the standard nutrition lecture currently given at Carolinas Rehabilitation to all inpatients with spinal cord injuries. This one lecture is what is required by Commission on Accreditation for Rehabilitation Facilities (CARF)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eat Smart, Live Better
Description: Intervention participants will participate in a series of six, 60-minute small group sessions of interactive nutrition education discussions led by a Registered Dietitian delivered over 3 weeks. They will also have one follow-up comprehensive nutrition education session approximately 3 months after receipt of the Eat Smart, Live Better curriculum. In order to help us assess the effectiveness of the nutrition education program, we will assess nutrition behavior and knowledge at this time as well. Community participants in the treatment group will attend the sessions at Carolinas Rehabilitation (CR). The control participants from the community will come to CR for the one standard nutrition lecture. Caregivers and spouses of all of the participants will be encouraged to attend the sessions.
Study: NCT03765502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon Device (NG)
Description: NG devices will be provided empty of drug product

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GEK
Description: Used to administer glucagon intramuscularly (IM)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IM Glucagon
Description: Administered IM via GEK
Study: NCT01879280

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional pterional craniotomy
Description: In the standard pterional craniotomy group, the attachment of the temporalis will be cut and the temporalis will be mobilized prior to exposure of the underlying bony calvarium. This maneuver is currently accepted for use by the majority of neurosurgeons nationwide.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional pterional craniotomy
Description: In the standard pterional craniotomy group, the attachment of the temporalis will be cut and the temporalis will be mobilized prior to exposure of the underlying bony calvarium. This maneuver is currently accepted for use by the majority of neurosurgeons nationwide.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteoplastic craniotomy
Description: In the osteoplastic group, the temporalis will be left attached to the bony calvarium prior to exposure of the tumor. There are ways to turn a bone flap with the temporalis still attached (i.e., an osteoplastic craniotomy). However, this method is thought to be slightly more time-consuming and is used less often in many centers. Aside from the extra time involved, we do not feel that leaving the temporalis attached to the bony calvarium disadvantages the patient in any fashion and may--in fact--result in less post-operative morbidity.
Study: NCT01465295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical hemiepiphysiodesis using the HemiBridge System
Description: Surgical application of mechanical hemiepiphysiodesis using the HemiBridge device.
Study: NCT04322175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: Meloxicam Eye Drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: Meloxicam Eye Drops
Study: NCT03919942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OxyFlower gel
Description: the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel
Description: the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal
Study: NCT01245166

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Acarbose 50 mg, per orem, thrice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin/Acarbose
Description: Metformin HCl 500 mg plus Acarbose 50 mg Tablets, per orem, thrice daily
Study: NCT03129269

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI and PET scan
Description: Neuroimaging with MRI and PET scan Amyloid tracer : For PET-scans, 4 MBq/kg of \[18F\]AV-45 will be injected into each subject in an intravenous bolus.
Study: NCT03678636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver antimicrobial dressing
Description: Silver dressing suitable for exudate level

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Usual care for wound type and condition
Study: NCT02422823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine
Description: Injection of 1.8mL of 4% articaine with 1: 100,000 epinephrine in block the inferior alveolar nerve in patients with irreversible pulpitis of mandibular molar in 40 patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine
Description: Injection of 3.6mL of 4% articaine with 1: 100,000 epinephrine in block the inferior alveolar nerve in patients with irreversible pulpitis of mandibular molar in 40 patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Study: NCT03747822

Intervention type: PROCEDURE
Group type: OTHER
Intervention: fat filler,PEEK,sliding genioplasty
Description: The procedure will be done under general anesthesia; the donor site lower abdomen, flank, lateral thigh, or inner thigh will be infused using a solution that consisted of 100 ml of normal saline with 50 mg (0.05%) of lidocaine and 0.1 ml of epinephrine. Liposuction will be performed using a 2-mm blunt cannula. A 20-cc syringe will be used to collect the fat. The fat will be injected into the chin in a supraperiosteal (subcutaneous) plane with a blunt 2-mm cannula using a fanning technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fat filler,PEEK,sliding genioplasty
Description: The procedure will be done under general anesthesia; the donor site lower abdomen, flank, lateral thigh, or inner thigh will be infused using a solution that consisted of 100 ml of normal saline with 50 mg (0.05%) of lidocaine and 0.1 ml of epinephrine. Liposuction will be performed using a 2-mm blunt cannula. A 20-cc syringe will be used to collect the fat. The fat will be injected into the chin in a supraperiosteal (subcutaneous) plane with a blunt 2-mm cannula using a fanning technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fat filler,PEEK,sliding genioplasty
Description: The procedure will be done under general anesthesia; the donor site lower abdomen, flank, lateral thigh, or inner thigh will be infused using a solution that consisted of 100 ml of normal saline with 50 mg (0.05%) of lidocaine and 0.1 ml of epinephrine. Liposuction will be performed using a 2-mm blunt cannula. A 20-cc syringe will be used to collect the fat. The fat will be injected into the chin in a supraperiosteal (subcutaneous) plane with a blunt 2-mm cannula using a fanning technique.
Study: NCT02635100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPAP machine with MNT algorithm
Description: The multinight (MNT) algorithm will be evaluated on patients with Obstructive Sleep Apnea (OSA) over multiple nights while using CPAP in the home for a total of 45 days. In particular the main goal is to assess the behavior of the two main stages of the algorithm:~1. Fast Track (FT) stage. Assesses if the algorithm reliably and timely reaches approximate therapeutic pressure levels.~2. Slow Titration (ST) stage.Assesses if data samples are appropriately collected in a pressure range so that the therapeutic pressure can be inferred according to the algorithm proposed.~   1. Five days with standard auto titration.~  2. MNT algorithm : 7 days (maximum) with Fast Track mode, 27 days (maximum) in Slow Titration mode. After PMNT is found, the device remains at PMNT for 5 sessions. Total approximately 45 days.
Study: NCT01824758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Group L lidocaine (0.5 mg/kg), (rocuronium) (0.05mg/kg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Group E: esmolol (1 mg/kg), (rocuronium) (0.05mg/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rocuronium
Description: 0.05 mg/kg rocuronium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rocuronium
Description: 0.05 mg/kg rocuronium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rocuronium
Description: 0.05 mg/kg rocuronium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group C: Placebo (NaCl 0.9%, 5 ml), (rocuronium) (0.05mg/kg)
Study: NCT02585700

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine, split inactivated
Description: Seasonal trivalent inactivated influenza vaccine (TIV), inactivated split virion, purified by sucrose gradient ultracentrifugation. The vaccine is produced in hen's eggs, and inactivated with beta-propiolactone.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL of phosphate buffered saline
Study: NCT01421706

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sibutramine-clopidogrel
Description: Sibutramine-clopidogrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sibutramine-Clarithromycin
Description: sibutramine-Clarithromycin
Study: NCT01619826

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: 9-month afterschool program designed to increase physical activity and aerobic fitness.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physical Activity
Description: Participants in this group partake in their regular afterschool activities, without intervention from the study staff.
Study: NCT04276883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual film containing Dexmedetomidine (BXCL501)
Description: Sublingual film containing Dexmedetomidine (BXCL501)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual film containing Dexmedetomidine (BXCL501)
Description: Sublingual film containing Dexmedetomidine (BXCL501)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Film
Description: Placebo Film for BXCL501
Study: NCT02820922

Intervention type: PROCEDURE
Intervention: Orthopedic
Description: anesthesia techniques with regard to age, sex, ASA score, anaesthesia technique, comorbidities, surgery diagnosis, length of surgery, complications and admission to intensive care unit after surgery
Study: NCT00450307

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody 3F8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Study: NCT02009800

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Description: One dose of Gardasil administered in the intervention group
Study: NCT03110315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: See detailed information in associated Arm Description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic suvorexant 10 mg tablet.
Study: NCT02166697

Intervention type: DRUG
Intervention: candesartan cilexetil
Description: candesartan cilexetil tablets
Study: NCT06277193

Intervention type: DIAGNOSTIC_TEST
Intervention: valuation of balance status, fear of falling and risk of falling in patients non-sarcopenia.
Description: Daily living activities, frailty, physical performance, balance status, risk of falling, fear of falling, nutritional status, and mental status were evaluated with various scales.

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of balance status, fear of falling and risk of falling in patients with probable sarcopenia.
Description: Daily living activities, frailty, physical performance, balance status, risk of falling, fear of falling, nutritional status, and mental status were evaluated with various scales.

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of balance status, fear of falling and risk of falling in patients with sarcopenia.
Description: Daily living activities, frailty, physical performance, balance status, risk of falling, fear of falling, nutritional status, and mental status were evaluated with various scales.

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of balance status, fear of falling and risk of falling in patients with severe sarcopenia.
Description: Daily living activities, frailty, physical performance, balance status, risk of falling, fear of falling, nutritional status, and mental status were evaluated with various scales.
Study: NCT00527800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Description: Once daily for 3 days, given in fixed dose tablets (40 mg dihydroartemisinin + 320 mg piperaquine) according to weight-based guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine
Description: Dosed twice daily for 3 days, given in fixed dose tablets (20 mg artemether + 120 mg lumefantrine) according to weight-based guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Description: Once daily dosing according to weight based guidelines
Study: NCT01911195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISOFLURANE- Experimental Arm
Description: The experimental group will be given the anesthetic isoflurane for three hours, and will undergo cognitive tests immediately following emergence from general anesthesia while connected to an EEG machine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group: Cognitive Testing
Description: The control group will undergo cognitive testing while connected to an EEG machine following a comparable rest period, but will not receive general anesthesia.
Study: NCT04333706

Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: Capecitabine 1000 mg BID

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sarilumab 150mg or 200 mg plus Capecitabine
Description: Sarilumab 150mg or 200 mg plus Capecitabine 1000 mg BID

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sarilumab 150mg or 200 mg plus Capecitabine
Description: Sarilumab 150mg or 200 mg plus Capecitabine 1000 mg BID

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sarilumab 150mg plus Capecitabine
Description: Dose escalation schedule of sarilumab. The starting dose for sarilumab is 150 mg SQ every 21 days, given 3 days prior to the first 4 of 8 cycles of capecitabine 1000 mg BID.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sarilumab 150mg plus Capecitabine
Description: Dose escalation schedule of sarilumab. The starting dose for sarilumab is 150 mg SQ every 21 days, given 3 days prior to the first 4 of 8 cycles of capecitabine 1000 mg BID.
Study: NCT04442776

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: D-AIP
Description: Intervention on change motivation, insight, medication adherence, drug consumption abstinence or reduction, therapeutic alliance, hopelessness and anxiety
Study: NCT01747603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specialized LPTB clinic
Description: 50% of enrolled infants will be randomized to the specialized LPTB follow-up clinic.
Study: NCT04488575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP1815
Description: EDP1815 is an orally administered monoclonal microbe

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsule
Study: NCT01595503

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rTMS with fMRI-based targeting
Description: Inhibitory (low frequency) 1-Hz rTMS will be applied to the secondary auditory cortex during 10 daily 20-minute treatment sessions. An fMRI scan combined with a language task will be used to localize the secondary auditory cortex, followed by neuronavigation to identify the scalp location overlying the targeted cortex.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS with landmark-based targeting
Description: Inhibitory (low frequency) 1-Hz rTMS will be applied over the left temporoparietal cortex (TPC) during 10 daily 20-minute treatment sessions, with the stimulating coil located midway between the left temporal (T3) and parietal (P3) scalp landmarks, using the International 10-20 system for EEG.
Study: NCT01672190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Therapy Program
Study: NCT04812756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step-2-It - text messaging program
Description: participants received a pedometer and text messages to motivate them to increase walking daily for a period of 12 weeks.
Study: NCT01860248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Description: The Vapocoolant spray containing alkane is applied for 20 seconds.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water spray
Description: This spray is covered so the patient and the investigator can not find the spray type out.